Clinicomorphological observation of refractory hepatoblastoma: a case report
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-3.14855Keywords:
CD10, hepatoblastoma, immunohistochemical characteristics, prognostic factorsAbstract
Summary. The clinical case of refractory hepatoblastoma with lethal outcome followed by pathomorphological verification has been analyzed. The true causes of hepatoblastoma development remain unknown. The prognostic factors of the disease require detailed study in complex investigations that would include histological, clinical, laboratory, and immunohistochemical characteristics. However, comparing clinical and histopathological parameters with CD10 expression could have a diagnostic role and may be useful in understanding tumorigenesis and prognostic analysis of a given tumor.
References
Starchenko II, Dyachenko LV, Prylutskyi ОK, et al. The observation of congenital retroperitoneal large size neuroblastoma. Exp Oncol 2019; 41: 1–3.
Zhang Y, Zhang WL, Huang DS, et al. Clinical effectiveness of multimodality treatment on advanced pediatric hepatoblastoma. Eur Rev Med Pharmacol Sci 2014; 18: 1018–26.
Bosman F, Carneiro F, Hruban R, Theise ND (eds). WHO Classification of Tumours of the Digestive System. 4th edn. IARC Press: Lyon: 2010. 314 р.
Koh KN, Park M, Kim BE, et al. Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma. Pediatr Blood Cancer 2011; 57: 554–60.
Kiruthiga KG, Banumathi R, Soumitra S, et al. Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival. J Gastrointest Oncol 2018; 9: 326–37.
Zhang Q, Ming J, Zhang S, et al. A rare case of adult hepatoblastoma with neuroendocrine differentiation misdiagnosed as neuroendocrine tumor. Int J Clin Exp Pathol 2013; 6: 308–13.
Mishra D, Sunita S, Narayan G. Role of B cell development marker CD10 in cancer progression and prognosis. Mol Biol Int 2016; 2016: 4328697.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.